These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37885925)

  • 21. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study.
    Guo P; Pi X; Gao F; Li Q; Li D; Feng W; Cao W
    Front Oncol; 2022; 12():945915. PubMed ID: 36338683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Wang L; Lin L; Zhou W
    Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study.
    Li X; Chen B; An C; Cheng Z; Han Z; Liu F; Yu J; Liang P
    J Cancer Res Ther; 2020 Sep; 16(5):1027-1037. PubMed ID: 33004744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study.
    Gao Y; Lu H; Xiong Z
    Front Oncol; 2023; 13():1231359. PubMed ID: 38074659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT-guided
    Chen Z; Fu X; Qiu Z; Mu M; Jiang W; Wang G; Zhong Z; Qi H; Gao F
    Radiol Oncol; 2023 Mar; 57(1):127-139. PubMed ID: 36942903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study.
    Li HZ; Tan J; Tang T; An TZ; Li JX; Xiao YD
    J Hepatocell Carcinoma; 2021; 8():1311-1322. PubMed ID: 34754838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
    Zheng L; Li HL; Guo CY; Luo SX
    Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.
    Ma KP; Fu JX; Duan F; Wang MQ
    World J Gastrointest Oncol; 2024 Apr; 16(4):1236-1247. PubMed ID: 38660650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Yang H; Yang T; Qiu G; Liu J
    J Hepatocell Carcinoma; 2023; 10():1435-1443. PubMed ID: 37691972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
    Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
    Front Oncol; 2022; 12():980214. PubMed ID: 36249023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy.
    Ni JY; Sun HL; Luo JH; Jiang XY; Chen D; Wang WD; Chen YT; Huang JH; Xu LF
    Cancer Manag Res; 2019; 11():9939-9950. PubMed ID: 32063720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial.
    Huang ZM; Han X; Wang J; Gu L; Tang L; Wu SY; Di T; Hou YW; Lau WY; Jiang YQ; Huang JH
    Liver Cancer; 2024 Aug; 13(4):438-450. PubMed ID: 39114763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.